Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
about
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingThe clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinomaActivation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.
P2860
Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Treatment-related fatigue with ...... a-analysis of clinical trials.
@en
Treatment-related fatigue with ...... a-analysis of clinical trials.
@nl
type
label
Treatment-related fatigue with ...... a-analysis of clinical trials.
@en
Treatment-related fatigue with ...... a-analysis of clinical trials.
@nl
prefLabel
Treatment-related fatigue with ...... a-analysis of clinical trials.
@en
Treatment-related fatigue with ...... a-analysis of clinical trials.
@nl
P2093
P2860
P1433
P1476
Treatment-related fatigue with ...... a-analysis of clinical trials.
@en
P2093
P2860
P2888
P304
P356
10.1007/S13277-014-2669-3
P577
2014-10-04T00:00:00Z